RxDoctor Payments Data

John Stevenson, MD

Internal Medicine · Pembroke, MANPI 1043284789

Payments from drug & device makers

$110in general payments, 2019–2025

Across 4 payments — averaging $27.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mannkind Corporation$43
  • Lilly USA, LLC$25
  • Neurocrine Biosciences, Inc.$24
  • Sanofi Pasteur Inc.$18

What the payments were for

  • Food & beverage$6761%
  • Education$4339%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$110 in reported general payments places this provider in the 60th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$547,348
Medicare patients
2,301
Services billed
4,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban2,696$748,113
TrulicityDulaglutide187$142,537
XareltoRivaroxaban528$135,164
NuplazidPimavanserin Tartrate55$118,503
EnbrelEtanercept12$94,455
Austedo XrDeutetrabenazine25$90,260
JanuviaSitagliptin Phosphate315$86,769
JardianceEmpagliflozin291$73,642
Dupixent SyringeDupilumab19$70,278
EntrestoSacubitril/Valsartan204$64,829
MyrbetriqMirabegron242$57,413
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$50,995
Breo ElliptaFluticasone/Vilanterol113$48,700
TradjentaLinagliptin122$36,754
XifaxanRifaximin13$36,228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$25$142,537187 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Pembroke

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →